Results
|
|
1.
|
Intrapericardial Left Ventricular Assist Device for Advanced Heart Failure. MedStar authors:
- Boyce, Steven W
- Najjar, Samer S
Year: 2017
Citation: - New England Journal of Medicine. 376(5):451-460, 2017 02 02
Institution: - MedStar Heart & Vascular Institute
Medline publication type:
- Comparative Study
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Aaronson KD, Anderson AS, Bhat G, Birks EJ, Boyce SW, Frazier OH, Gregoric ID, Jeevanandam V, Leadley K, Mallidi H, Milano CA, Najjar SS, Pagani FD, Rogers JG, Slaughter MS, Tatooles AJ
|
|
|
2.
|
A Fully Magnetically Levitated Left Ventricular Assist Device - Final Report. MedStar authors:
- Molina, Ezequiel J
- Sheikh, Farooq
Year: 2019
Citation: - New England Journal of Medicine. 380(17):1618-1627, 2019 04 25.
Institution: - MedStar Heart & Vascular Institute
Medline publication type:
- Equivalence Trial
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Aaronson K, Babu A, Bhimaraj A, Bruckner BA, Chomsky D, Chuang J, Cleveland JC Jr, Cogswell R, Cotts WG, Dean D, Ewald GA, Goldstein DJ, Hutchins SW, Itoh A, Jeevanandam V, John R, Katz JN, Krishnamoorthy A, Lowes BD, Mangi AA, Mehra MR, Milano CA, Molina EJ, MOMENTUM 3 Investigators, Naka Y, Pagani FD, Patel CB, Ransom J, Raval NY, Salerno CT, Sayer G, Sheikh F, Silvestry SC, Sood P, Tatooles AJ, Tessmann PB, the MOMENTUM 3 Investigators, Topuria I, Um JY, Uriel N, Walsh MN, Yuzefpolskaya M
|
|
|
3.
|
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. MedStar authors:
Year: 2019
Citation: - Lancet Oncology. 20(1):88-99, 2019 01.
Institution: - MedStar Franklin Square Medical Center
Medline publication type:
All authors: - Bandos H, Brufsky AM, Chia SK, Dakhil SR, Fehrenbacher L, Geyer CE Jr, Graham ML, Jeong JH, Lembersky BC, Mamounas EP, McCarron EC, Paik S, Rastogi P, Seay TE, Soori GS, Swain SM, Wade JL 3rd, Walshe JM, Wickerham DL, Wolmark N
|
|
|
4.
|
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. MedStar authors:
Year: 2013
Citation: - Lancet Oncology. 14(6):461-71, 2013 May.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Benyunes MC, Campone M, Ciruelos E, Clark E, Cortes J, Ferrero JM, Kim SB, Knott A, Ro J, Ross G, Schneeweiss A, Semiglazov V, Swain SM
|
